(HCA) HCA Holdings - Overview
Exchange: NYSE •
Country: United States •
Currency: USD •
Type: Common Stock •
ISIN: US40412C1018
Stock: Hospitals, Outpatient Clinics, Surgery Centers, Behavioral Facilities
Total Rating 66
Risk 75
Buy Signal -0.04
EPS (Earnings per Share)
Revenue
Dividends
| Dividend Yield | 0.75% |
| Yield on Cost 5y | 2.13% |
| Yield CAGR 5y | 10.67% |
| Payout Consistency | 55.5% |
| Payout Ratio | 8.4% |
| Risk 5d forecast | |
|---|---|
| Volatility | 30.6% |
| Relative Tail Risk | -3.20% |
| Reward TTM | |
|---|---|
| Sharpe Ratio | 1.52 |
| Alpha | 41.73 |
| Character TTM | |
|---|---|
| Beta | 0.309 |
| Beta Downside | 0.371 |
| Drawdowns 3y | |
|---|---|
| Max DD | 28.45% |
| CAGR/Max DD | 0.93 |
Description: HCA HCA Holdings January 28, 2026
HCA Healthcare, Inc. (NYSE:HCA) operates a nationwide network of acute-care hospitals and a broad suite of outpatient facilities-including freestanding surgery centers, emergency care sites, urgent-care clinics, imaging and oncology centers, and behavioral health hospitals-providing inpatient, surgical, diagnostic, and therapeutic services across the United States.
Key recent metrics (Q4 2025 / FY 2025):
• Revenue ≈ $15.2 billion, up 4.1 % YoY, driven by higher case mix and modest price-inflation in Medicare and commercial contracts.
• Adjusted EBITDA ≈ $4.3 billion (EBITDA margin ≈ 28 %), reflecting continued cost-discipline despite labor-market pressure.
• Hospital occupancy averaged 84 % (vs. 81 % in FY 2024), while outpatient volume grew 6 % YoY, underscoring the shift toward ambulatory care.
• Sector drivers: an aging U.S. population (+1.2 % annual growth in the 65+ cohort), rising chronic-disease prevalence, and incremental Medicare reimbursement adjustments (e.g., FY 2025’s 1.5 % outpatient rate increase) support demand for HCA’s diversified service lines.
For a deeper quantitative assessment, see the HCA profile on ValueRay.
Piotroski VR‑10 (Strict, 0-10) 8.0
| Net Income: 6.78b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.13 > 0.02 and ΔFCF/TA 3.19 > 1.0 |
| NWC/Revenue: -3.69% < 20% (prev 1.75%; Δ -5.44% < -1%) |
| CFO/TA 0.21 > 3% & CFO 12.64b > Net Income 6.78b |
| Net Debt (49.16b) to EBITDA (15.60b): 3.15 < 3 |
| Current Ratio: 0.83 > 1.5 & < 3 |
| Outstanding Shares: last quarter (230.7m) vs 12m ago -9.64% < -2% |
| Gross Margin: 41.50% > 18% (prev 0.15%; Δ 4135 % > 0.5%) |
| Asset Turnover: 125.8% > 50% (prev 118.6%; Δ 7.12% > 0%) |
| Interest Coverage Ratio: 5.37 > 6 (EBITDA TTM 15.60b / Interest Expense TTM 2.25b) |
Altman Z'' 0.68
| A: -0.05 (Total Current Assets 13.56b - Total Current Liabilities 16.35b) / Total Assets 60.72b |
| B: -0.08 (Retained Earnings -5.03b / Total Assets 60.72b) |
| C: 0.20 (EBIT TTM 12.08b / Avg Total Assets 60.12b) |
| D: -0.09 (Book Value of Equity -6.03b / Total Liabilities 63.49b) |
| Altman-Z'' Score: 0.68 = B |
Beneish M -3.49
| DSRI: 0.94 (Receivables 10.87b/10.75b, Revenue 75.60b/70.60b) |
| GMI: 0.36 (GM 41.50% / 14.94%) |
| AQI: 1.36 (AQ_t 0.26 / AQ_t-1 0.19) |
| SGI: 1.07 (Revenue 75.60b / 70.60b) |
| TATA: -0.10 (NI 6.78b - CFO 12.64b) / TA 60.72b) |
| Beneish M-Score: -3.49 (Cap -4..+1) = AA |
What is the price of HCA shares?
As of February 03, 2026, the stock is trading at USD 496.85 with a total of 953,971 shares traded.
Over the past week, the price has changed by +5.18%, over one month by +5.63%, over three months by +7.81% and over the past year by +49.74%.
Over the past week, the price has changed by +5.18%, over one month by +5.63%, over three months by +7.81% and over the past year by +49.74%.
Is HCA a buy, sell or hold?
HCA Holdings has received a consensus analysts rating of 4.08.
Therefore, it is recommended to buy HCA.
- StrongBuy: 13
- Buy: 2
- Hold: 9
- Sell: 1
- StrongSell: 0
What are the forecasts/targets for the HCA price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 527.6 | 6.2% |
| Analysts Target Price | 527.6 | 6.2% |
| ValueRay Target Price | 642.1 | 29.2% |
HCA Fundamental Data Overview January 31, 2026
P/E Trailing = 17.0385
P/E Forward = 15.9744
P/S = 1.4935
P/B = 293.44
P/EG = 1.1738
Revenue TTM = 75.60b USD
EBIT TTM = 12.08b USD
EBITDA TTM = 15.60b USD
Long Term Debt = 41.60b USD (from longTermDebt, last quarter)
Short Term Debt = 6.74b USD (from shortTermDebt, last quarter)
Debt = 50.20b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 49.16b USD (from netDebt column, last quarter)
Enterprise Value = 162.07b USD (112.91b + Debt 50.20b - CCE 1.04b)
Interest Coverage Ratio = 5.37 (Ebit TTM 12.08b / Interest Expense TTM 2.25b)
EV/FCF = 21.07x (Enterprise Value 162.07b / FCF TTM 7.69b)
FCF Yield = 4.75% (FCF TTM 7.69b / Enterprise Value 162.07b)
FCF Margin = 10.17% (FCF TTM 7.69b / Revenue TTM 75.60b)
Net Margin = 8.97% (Net Income TTM 6.78b / Revenue TTM 75.60b)
Gross Margin = 41.50% ((Revenue TTM 75.60b - Cost of Revenue TTM 44.23b) / Revenue TTM)
Gross Margin QoQ = 41.90% (prev 41.83%)
Tobins Q-Ratio = 2.67 (Enterprise Value 162.07b / Total Assets 60.72b)
Interest Expense / Debt = 1.14% (Interest Expense 572.0m / Debt 50.20b)
Taxrate = 19.05% (509.0m / 2.67b)
NOPAT = 9.78b (EBIT 12.08b * (1 - 19.05%))
Current Ratio = 0.83 (Total Current Assets 13.56b / Total Current Liabilities 16.35b)
Debt / Equity = -8.33 (negative equity) (Debt 50.20b / totalStockholderEquity, last quarter -6.03b)
Debt / EBITDA = 3.15 (Net Debt 49.16b / EBITDA 15.60b)
Debt / FCF = 6.39 (Net Debt 49.16b / FCF TTM 7.69b)
Total Stockholder Equity = -4.82b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.28% (Net Income 6.78b / Total Assets 60.72b)
RoE = -140.8% (negative equity) (Net Income TTM 6.78b / Total Stockholder Equity -4.82b)
RoCE = 32.84% (EBIT 12.08b / Capital Employed (Equity -4.82b + L.T.Debt 41.60b))
RoIC = 24.38% (NOPAT 9.78b / Invested Capital 40.11b)
WACC = 5.16% (E(112.91b)/V(163.11b) * Re(7.05%) + D(50.20b)/V(163.11b) * Rd(1.14%) * (1-Tc(0.19)))
Discount Rate = 7.05% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -7.76%
[DCF Debug] Terminal Value 88.37% ; FCFF base≈6.87b ; Y1≈8.42b ; Y5≈14.11b
Fair Price DCF = 1586 (EV 411.13b - Net Debt 49.16b = Equity 361.97b / Shares 228.2m; r=5.90% [WACC]; 5y FCF grow 24.08% → 2.90% )
EPS Correlation: 89.07 | EPS CAGR: 19.40% | SUE: 1.24 | # QB: 4
Revenue Correlation: 98.76 | Revenue CAGR: 7.37% | SUE: -0.44 | # QB: 0
EPS next Quarter (2026-03-31): EPS=7.20 | Chg30d=+0.031 | Revisions Net=-3 | Analysts=17
EPS current Year (2026-12-31): EPS=30.18 | Chg30d=+0.453 | Revisions Net=-3 | Growth EPS=+7.0% | Growth Revenue=+4.0%
EPS next Year (2027-12-31): EPS=33.19 | Chg30d=+0.253 | Revisions Net=-3 | Growth EPS=+10.0% | Growth Revenue=+4.9%
P/E Forward = 15.9744
P/S = 1.4935
P/B = 293.44
P/EG = 1.1738
Revenue TTM = 75.60b USD
EBIT TTM = 12.08b USD
EBITDA TTM = 15.60b USD
Long Term Debt = 41.60b USD (from longTermDebt, last quarter)
Short Term Debt = 6.74b USD (from shortTermDebt, last quarter)
Debt = 50.20b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 49.16b USD (from netDebt column, last quarter)
Enterprise Value = 162.07b USD (112.91b + Debt 50.20b - CCE 1.04b)
Interest Coverage Ratio = 5.37 (Ebit TTM 12.08b / Interest Expense TTM 2.25b)
EV/FCF = 21.07x (Enterprise Value 162.07b / FCF TTM 7.69b)
FCF Yield = 4.75% (FCF TTM 7.69b / Enterprise Value 162.07b)
FCF Margin = 10.17% (FCF TTM 7.69b / Revenue TTM 75.60b)
Net Margin = 8.97% (Net Income TTM 6.78b / Revenue TTM 75.60b)
Gross Margin = 41.50% ((Revenue TTM 75.60b - Cost of Revenue TTM 44.23b) / Revenue TTM)
Gross Margin QoQ = 41.90% (prev 41.83%)
Tobins Q-Ratio = 2.67 (Enterprise Value 162.07b / Total Assets 60.72b)
Interest Expense / Debt = 1.14% (Interest Expense 572.0m / Debt 50.20b)
Taxrate = 19.05% (509.0m / 2.67b)
NOPAT = 9.78b (EBIT 12.08b * (1 - 19.05%))
Current Ratio = 0.83 (Total Current Assets 13.56b / Total Current Liabilities 16.35b)
Debt / Equity = -8.33 (negative equity) (Debt 50.20b / totalStockholderEquity, last quarter -6.03b)
Debt / EBITDA = 3.15 (Net Debt 49.16b / EBITDA 15.60b)
Debt / FCF = 6.39 (Net Debt 49.16b / FCF TTM 7.69b)
Total Stockholder Equity = -4.82b (last 4 quarters mean from totalStockholderEquity)
RoA = 11.28% (Net Income 6.78b / Total Assets 60.72b)
RoE = -140.8% (negative equity) (Net Income TTM 6.78b / Total Stockholder Equity -4.82b)
RoCE = 32.84% (EBIT 12.08b / Capital Employed (Equity -4.82b + L.T.Debt 41.60b))
RoIC = 24.38% (NOPAT 9.78b / Invested Capital 40.11b)
WACC = 5.16% (E(112.91b)/V(163.11b) * Re(7.05%) + D(50.20b)/V(163.11b) * Rd(1.14%) * (1-Tc(0.19)))
Discount Rate = 7.05% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 7.95%
Shares Correlation 3-Years: -100.0 | Cagr: -7.76%
[DCF Debug] Terminal Value 88.37% ; FCFF base≈6.87b ; Y1≈8.42b ; Y5≈14.11b
Fair Price DCF = 1586 (EV 411.13b - Net Debt 49.16b = Equity 361.97b / Shares 228.2m; r=5.90% [WACC]; 5y FCF grow 24.08% → 2.90% )
EPS Correlation: 89.07 | EPS CAGR: 19.40% | SUE: 1.24 | # QB: 4
Revenue Correlation: 98.76 | Revenue CAGR: 7.37% | SUE: -0.44 | # QB: 0
EPS next Quarter (2026-03-31): EPS=7.20 | Chg30d=+0.031 | Revisions Net=-3 | Analysts=17
EPS current Year (2026-12-31): EPS=30.18 | Chg30d=+0.453 | Revisions Net=-3 | Growth EPS=+7.0% | Growth Revenue=+4.0%
EPS next Year (2027-12-31): EPS=33.19 | Chg30d=+0.253 | Revisions Net=-3 | Growth EPS=+10.0% | Growth Revenue=+4.9%